Cargando…
Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis
AIMS: Heart failure is an increasingly recognized later stage manifestation of arrhythmogenic right ventricular cardiomyopathy (ARVC) that can require heart transplantation (HT) to appropriately treat. We aimed to study contemporary ARVC HT outcomes in a national registry. METHODS AND RESULTS: The U...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934952/ https://www.ncbi.nlm.nih.gov/pubmed/35132806 http://dx.doi.org/10.1002/ehf2.13687 |
_version_ | 1784671940821123072 |
---|---|
author | Giuliano, Katherine Scheel, Paul Etchill, Eric Fraser, Charles D. Suarez‐Pierre, Alejandro Hsu, Steven Wittstein, Ilan S. Kasper, Edward K. Florido, Roberta Tandri, Harikrishna Calkins, Hugh Choi, Chun W. Sharma, Kavita Kilic, Ahmet Gilotra, Nisha A. |
author_facet | Giuliano, Katherine Scheel, Paul Etchill, Eric Fraser, Charles D. Suarez‐Pierre, Alejandro Hsu, Steven Wittstein, Ilan S. Kasper, Edward K. Florido, Roberta Tandri, Harikrishna Calkins, Hugh Choi, Chun W. Sharma, Kavita Kilic, Ahmet Gilotra, Nisha A. |
author_sort | Giuliano, Katherine |
collection | PubMed |
description | AIMS: Heart failure is an increasingly recognized later stage manifestation of arrhythmogenic right ventricular cardiomyopathy (ARVC) that can require heart transplantation (HT) to appropriately treat. We aimed to study contemporary ARVC HT outcomes in a national registry. METHODS AND RESULTS: The United Network for Organ Sharing registry was queried for HT recipients from 1/1994 through 2/2020. ARVC patients were compared with non‐ARVC dilated, restrictive, and hypertrophic cardiomyopathy HT patients (HT for ischaemic and valvular disease was excluded from analysis). Post‐HT survival was assessed using Kaplan–Meier estimates. A total of 189 of 252 (75%) waitlisted ARVC patients (median age 48 years, 65% male) underwent HT, representing 0.3% of the total 65 559 HT during the study time period. Annual frequency of HT for ARVC increased significantly over time. ARVC patients had less diabetes (5% vs. 17%, P < 0.001), less cigarette use (15% vs. 23%, P < 0.001), lower pulmonary artery and pulmonary capillary wedge pressures, and lower cardiac output than the 33 659 non‐ARVC patients (P < 0.001). Ventricular assist device use was significantly lower in ARVC patients (8% vs. 32%, P < 0.001); 1 and 5 year post‐HT survival was 97% and 93% for ARVC vs. 95% and 82% for non‐ARVC HT recipients (P < 0.001). On adjusted multivariable Cox regression, ARVC had decreased risk of post‐HT death compared with non‐ARVC aetiologies (hazard ratio 0.48, 95% confidence interval 0.28–0.82, P = 0.008). Patients with ARVC also had lower risk of death or graft failure than non‐ARVC patients (hazard ratio 0.51, 95% confidence interval 0.32–0.81, P = 0.004). CONCLUSIONS: In the largest series of HT in ARVC, we found that HT is increasingly performed in ARVC, with higher survival compared with other cardiomyopathy aetiologies. The right ventricular predominant pathophysiology may require unique considerations for heart failure management, including HT. |
format | Online Article Text |
id | pubmed-8934952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89349522022-03-24 Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis Giuliano, Katherine Scheel, Paul Etchill, Eric Fraser, Charles D. Suarez‐Pierre, Alejandro Hsu, Steven Wittstein, Ilan S. Kasper, Edward K. Florido, Roberta Tandri, Harikrishna Calkins, Hugh Choi, Chun W. Sharma, Kavita Kilic, Ahmet Gilotra, Nisha A. ESC Heart Fail Original Articles AIMS: Heart failure is an increasingly recognized later stage manifestation of arrhythmogenic right ventricular cardiomyopathy (ARVC) that can require heart transplantation (HT) to appropriately treat. We aimed to study contemporary ARVC HT outcomes in a national registry. METHODS AND RESULTS: The United Network for Organ Sharing registry was queried for HT recipients from 1/1994 through 2/2020. ARVC patients were compared with non‐ARVC dilated, restrictive, and hypertrophic cardiomyopathy HT patients (HT for ischaemic and valvular disease was excluded from analysis). Post‐HT survival was assessed using Kaplan–Meier estimates. A total of 189 of 252 (75%) waitlisted ARVC patients (median age 48 years, 65% male) underwent HT, representing 0.3% of the total 65 559 HT during the study time period. Annual frequency of HT for ARVC increased significantly over time. ARVC patients had less diabetes (5% vs. 17%, P < 0.001), less cigarette use (15% vs. 23%, P < 0.001), lower pulmonary artery and pulmonary capillary wedge pressures, and lower cardiac output than the 33 659 non‐ARVC patients (P < 0.001). Ventricular assist device use was significantly lower in ARVC patients (8% vs. 32%, P < 0.001); 1 and 5 year post‐HT survival was 97% and 93% for ARVC vs. 95% and 82% for non‐ARVC HT recipients (P < 0.001). On adjusted multivariable Cox regression, ARVC had decreased risk of post‐HT death compared with non‐ARVC aetiologies (hazard ratio 0.48, 95% confidence interval 0.28–0.82, P = 0.008). Patients with ARVC also had lower risk of death or graft failure than non‐ARVC patients (hazard ratio 0.51, 95% confidence interval 0.32–0.81, P = 0.004). CONCLUSIONS: In the largest series of HT in ARVC, we found that HT is increasingly performed in ARVC, with higher survival compared with other cardiomyopathy aetiologies. The right ventricular predominant pathophysiology may require unique considerations for heart failure management, including HT. John Wiley and Sons Inc. 2022-02-08 /pmc/articles/PMC8934952/ /pubmed/35132806 http://dx.doi.org/10.1002/ehf2.13687 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Giuliano, Katherine Scheel, Paul Etchill, Eric Fraser, Charles D. Suarez‐Pierre, Alejandro Hsu, Steven Wittstein, Ilan S. Kasper, Edward K. Florido, Roberta Tandri, Harikrishna Calkins, Hugh Choi, Chun W. Sharma, Kavita Kilic, Ahmet Gilotra, Nisha A. Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis |
title | Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis |
title_full | Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis |
title_fullStr | Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis |
title_full_unstemmed | Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis |
title_short | Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis |
title_sort | heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934952/ https://www.ncbi.nlm.nih.gov/pubmed/35132806 http://dx.doi.org/10.1002/ehf2.13687 |
work_keys_str_mv | AT giulianokatherine hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis AT scheelpaul hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis AT etchilleric hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis AT frasercharlesd hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis AT suarezpierrealejandro hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis AT hsusteven hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis AT wittsteinilans hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis AT kasperedwardk hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis AT floridoroberta hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis AT tandriharikrishna hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis AT calkinshugh hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis AT choichunw hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis AT sharmakavita hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis AT kilicahmet hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis AT gilotranishaa hearttransplantationoutcomesinarrhythmogenicrightventricularcardiomyopathyacontemporarynationalanalysis |